meaningful endorsements, importantly, key drive which quarters and including leadership and you, Thank some been expansion, demographic Robert, developments all of efficiencies, growth our our to recent our I'm along around execution, of the interest, our going making, operational discuss the academic developments, This the our with morning, new good most educational will morning, strengthening ahead. everyone. we've progress in investments, market that
territory doing. leadership conducted we've I've mentioned, each as August, are the dive We're know our modifications sessions spending I in that detailed some functional are areas. done know adjustments of Fennec joining multiple to we across I with Robert in historical several not. including making deep I've of teams planning a since business. So where and been our where getting business, we selective the senior
our to long-term that our spared align drive it's I've into cancer ears and imperatives first growth and We to reminder, five also pillars and by U.S. company's patients years and and to in place the going threat reduce treatments. and to drive are again, in hearing Europe loss to a ensure the goals profound hardships their brand loss. the of with coming risk going which, with with that come.
These their the actions of hearing put vision the the protecting for objectives for approved only are and months the our against my PEDMARK, all execution some cisplatin ototoxicity eligible are strategic platinum-treated to are vision as therapy team associated permanent
the the awareness to is -- oncologists with imperative importance Our the increasing patient first unmet the recognize CIO. need to around unmet and continuing preventing need the drive of
initiative Our all PEDMARK for prevention. the care of standard second cementing as is CIO
PEDMARK. Fourth patients around confidence positive education PEDMARK. first with is across and advocacy, demand caregivers, ensure equally and throughout Third the is as PEDMARK's seamless HCPs important access but activating just through activation, is and the product. beyond providers and And for for disease oncologists, having them especially payers, continued experience our gain fifth offices adoption and
and quarter patients least opportunity annually in cell as significant we're The segment. in XX,XXX Young thyroid Adult the concept is with germ seeing the of and the that tumors addition the the AYA Adolescent developments to emerging cisplatin, proof including treated primary exciting at with most this segment such One of in tumors. pediatrics tumors is market
can are a leaders with reporting, that used compelling and I have and that for they how better I've them listened their them met and physicians these years, loss.
And avoid of the some have we in are personally to and hearing opinion I've reporting and patients them of AYA, know PEDMARK outcomes. help understanding months, the of Over many
AYA So greater much profile the a go The let pediatric than and the of size via me into the has market, more reimbursement for market the it AYA on is market. favorable detail market. reimbursement outpatient potential
or caused fact, reimbursement from quarter, the we to the the the PEDMARK. encouraged aware surpassed physicians of availability quarter, reduce cisplatin patients reminder, with AYA treating of age we've ototoxicity is AYA being In loss to a non-metastatic been month population the localized were treatment. third with X in the Most PEDMARK solid them, PEDMARK greater as tumors. indicated risk of a by being third of pediatric of of the response hearing and the very while in aware XX% PEDMARK than for Again, patients.
Including associated actively cisplatin as acutely older not preventative by in
NCCN you the by is As PEDMARK for Cancer know, the AYA Care recommended or population Network. Comprehensive the National
and PEDMARK the plans.
Further, at AYA with to within their able administer reimbursement us the showing quarter a So is patients here? several proof to focused partner platform the in administered successful were being of Orsini, so multiple patients AYA respective this what what third population gives in pharmacy and multiple specialty we QX, now the health quarters expanded homes. the confidence community, awareness in achieved Orsini us of After confidence with company major concept partnership activities in on
delivery to the is it's This and the enables of a stream. bag reminder, great all strong and provider is believe sustainable to what to administration insurance white home the Orsini Medicaid. the beginning a direct news, As revenue with or we hospital partnership billing
an seen the are vials health high STS, academic as which We increasing coming as patient institutions adoption we critical standards. the substitutions seeing are PEDMARK clinical centers in in Further, of PEDMARK. for Academic or major opportunity potential new as to orders versus repeating select expect per PEDMARK compounded patients. serious of patient risks XX AYA, pose setting and vials versions of per in example their the have we this ramp segment to over up quarters.
And centers
powerful, and awareness or We're hearing with address are up institutions strategic of potential adoption to and transition opens opinion broader market these associated initiatives this To the significant So a need engagements, key for risk signal with broader help ecosystems initiatives the for also cancer and PEDMARK. creating on these us positioning PEDMARK settings, drive in efforts acceptance.
This raise working ototoxicity unmet research include endorsement it's by educational opportunities treatment. permanent outreach, patients, which leader future select is cisplatin well ultimately to for loss all digital for of expansion.
these long-term initiatives the expect over value to to come. generating and We quarters continue the
in Fennec clinical investigator-initiated outside making we We and the terms is PEDMARQSI, In of providing look commercial as March trial Norgine PEDMARK with the months. ex-U.S. the following in the exclusive to the commercialize product Japan, to in the the to progress in launch that with agreement in we're additional Also announcement progresses expected PEDMARK XXXX Results treatment. sometime of the of U.S., the and in at evaluation frequency executed evaluating launch tumors. Japan forward this coming and/or in thereafter. with induced enrolled in launch UK future called licensing and front, both partnering end of will revenue of and source October generate updates solid an on the the safety efficacy these the and of is This XXXX. the for in countries. the Germany evaluates in in hearing of primary are registration trial XXXX.
The licensing potential PEDMARK of fully STS-JXX to impairment localized trial was AYAs children The ototoxicity assess the by of endpoint as expected PEDMARK trial cisplatin or reducing
I'd folks, like and team strengthened executive with a Finally, appointments to leadership we've them about few of our significantly now. talk
our We're marketing, field to business evolution. Fennec business trade, have Evans, Terry will reimbursement.
And lead engagement for strategy, and a Christiana in chapter First roles These medical lead Christy is organization's Officer. sales are medical Pierre is Chief to Cioffi, impact our is GPO and make our on training, big corporate regulatory. a embark experienced Officer; now critically important Christy Strategy Pierre affairs, development, expect Sayad, multi-talented and we Chief There's information, Commercial and who Chief alliance management. Officer. who management, sales Terry board. These new Medical lead Terry them delighted as operations, all and now our our leaders, very on will development Fennec. KOL and our and on are Pierre, we operations, will
mentioned, with Fennec's combined them upon biopharmaceutical and commercial accelerate executives, clinical, of seasoned are leadership, oncology significantly our build PEDMARK. for employee will industry I proven commercial with base sales, as All talented experience.
Their operation seamlessly our market strategy to ability execute and
partner of over go the and will to excellence, to Thank culture Christy and leadership so members through to you alignment, Robert me cross-functional creating the of join and organization. Robert? the some financials executional of operational Pierre, to of it strengthening efficiencies teams much.
And high-performing turn all our ensure with As to while Robert back now I'm team, Terry executive quarter. going this
